SDS Biotech K.K. reported consolidated earnings results for the six months ended June 30, 2014. For the period, on consolidated basis, the company reported net sales of ¥6,638 million against ¥4,591 million a year ago. Operating income was ¥337 million against operating loss of ¥114 million a year ago. Ordinary income was ¥230 million against ordinary loss of ¥114 million a year ago. Net income was ¥117 million or ¥15.00 per share against net loss of ¥74 million or ¥9.48 per share a year ago. Income before income taxes and minority interests was ¥228,312 million against loss before income taxes and minority interests of ¥115,223 million a year ago. Net cash provided by operating activities was ¥646,212 million against ¥423,400 million a year ago. Purchase of property, plant and equipment was ¥108,014 million against ¥102,206 million a year ago. Purchase of intangible assets was ¥8,172 million against ¥7,452 million a year ago.

The company provided consolidated earnings guidance for full year ending December 31, 2014. For the year, the company expects to report net sales of ¥14,866 million, operating income of ¥1,352 million, ordinary income of ¥1,179 million and net income of ¥684 million or ¥87.35 per share.

The company also announced dividend for the second quarter of 2014 and provided dividend guidance for the ending December 31, 2014. For the second quarter ended June 30, 2014, the company announced dividend of JPY 10.00 per share. The company paid year end dividend of JPY 10.00 per share for the second quarter ending June 30, 2013. The dividend is payable on September 8, 2014.

For the year ending December 31, 2014, the company expects full year dividend of JPY 20.00 per share including second quarter end dividend of JPY 10.00 per share. The company paid dividend of JPY 20.00 per share for the year ended December 31, 2013.